Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/25475
Title: Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
Authors: 
Mesh: 
Issue Date: 2016
Citation: PLoS ONE.2016;(11)8:e0161484
Abstract: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy.
PMID: 27557121
URI: https://hdl.handle.net/20.500.12530/25475
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC4996463.pdf911.35 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.